IntroductionAntibody–drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate develo…
BackgroundInsomnia is increasingly recognized as a systemic disorder involving persistent hyperarousal, neuroendocrine dysregulation, immune activation, and impaired stress adaptation. However, circulating biomarkers reflecting these interconnected bio…
IntroductionGlycoconjugate vaccines convert T-cell-independent polysaccharides into T-cell-dependent antigens, but the cellular dynamics of prime‑boost responses remain incompletely defined.MethodsMice were immunized with the W135 meningococcal conjuga…
BackgroundThe tumor microenvironment has emerged as an important determinant of response to immune checkpoint inhibitors (ICIs), with increasing attention directed toward stromal components such as cancer-associated fibroblasts (CAFs). Experimental evi…
ObjectiveTo evaluate the immunogenicity of a tetanus vaccine, adsorbed (TTVA) in people aged 18 years and above.MethodsA randomized, double-blinded, and positive controlled clinical trial was conducted in Bijie, Guizhou Province, China. Participants ag…
BackgroundLocally advanced non-small-cell lung cancer (LA-NSCLC) is a subtype of lung cancer with substantial heterogeneity in clinical prognosis. Immune injury induced by radiotherapy exposure is a critical factor affecting treatment response and long…
Decompression sickness (DCS) spinal cord injury (SCI) is a pivotal concern in diving activities, and prevention is the key. Our previous study found that hyperbaric oxygen (HBO) preconditioning reduced neurological deficit in DCS SCI rats, but the unde…
Background and objectivesProgression independent of relapse activity (PIRA) is increasingly recognized as a major driver of disability accumulation in multiple sclerosis (MS). However, the factors associated with PIRA occurring after initiation of high…
BackgroundTalquetamab, a first-in-class G protein–coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, demonstrates substantial clinical activity in relapsed/refractory multiple myeloma (RRMM). However, immune dysfunction asso…
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are established components of endocrine therapy for hormone receptor-positive (HR+), HER2-negative breast cancer. Beyond RB-dependent G1 arrest, these drugs alter antigen presentation, interferon sign…
